Close
Program description
GPCR target for metabolic diseases
- Discovery
- Candidate
- Preclinical
- Phase I
Initiated in 2022, the discovery collaboration focuses on a GPCR target involved in metabolic diseases.
The collaboration combines on the one hand, our expertise in the discovery of candidate targeting GPCR associating experience in GPCR Medicinal Chemistry and proprietary bioSens-All® technology to address GPCR pharmacology, and on the other hands, long-term knowledge of Prof. Michel Bouvier from UdM/IRIC in metabolic disease and animal models, and expertise of Ono as pharma partner to discover breakthrough therapeutics and bring it to the patients.
